JP4719356B2 - 抗ガン剤及びｄｎａ複製阻害剤 - Google Patents

抗ガン剤及びｄｎａ複製阻害剤 Download PDF

Info

Publication number
JP4719356B2
JP4719356B2 JP2000560859A JP2000560859A JP4719356B2 JP 4719356 B2 JP4719356 B2 JP 4719356B2 JP 2000560859 A JP2000560859 A JP 2000560859A JP 2000560859 A JP2000560859 A JP 2000560859A JP 4719356 B2 JP4719356 B2 JP 4719356B2
Authority
JP
Japan
Prior art keywords
cancer
thio
mmol
groups
arac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000560859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002521318A5 (OSRAM
JP2002521318A (ja
Inventor
サード ジョン・エー・セクリスト
カメル・エヌ・チワリ
ジョン・エー・モンゴメリー
Original Assignee
サザン・リサーチ・インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サザン・リサーチ・インスティテュート filed Critical サザン・リサーチ・インスティテュート
Publication of JP2002521318A publication Critical patent/JP2002521318A/ja
Publication of JP2002521318A5 publication Critical patent/JP2002521318A5/ja
Application granted granted Critical
Publication of JP4719356B2 publication Critical patent/JP4719356B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2000560859A 1998-07-23 1999-07-23 抗ガン剤及びｄｎａ複製阻害剤 Expired - Fee Related JP4719356B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9386998P 1998-07-23 1998-07-23
US60/093,869 1998-07-23
PCT/US1999/016630 WO2000004866A2 (en) 1998-07-23 1999-07-23 Preparation of thioarabinofuranosyl compounds and use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010102499A Division JP2010202655A (ja) 1998-07-23 2010-04-27 チオアラビノフラノシル化合物の製造方法
JP2010243705A Division JP5357857B2 (ja) 1998-07-23 2010-10-29 抗ガン剤及びｄｎａ複製阻害剤

Publications (3)

Publication Number Publication Date
JP2002521318A JP2002521318A (ja) 2002-07-16
JP2002521318A5 JP2002521318A5 (OSRAM) 2011-01-20
JP4719356B2 true JP4719356B2 (ja) 2011-07-06

Family

ID=22241386

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000560859A Expired - Fee Related JP4719356B2 (ja) 1998-07-23 1999-07-23 抗ガン剤及びｄｎａ複製阻害剤
JP2010102499A Pending JP2010202655A (ja) 1998-07-23 2010-04-27 チオアラビノフラノシル化合物の製造方法
JP2010243705A Expired - Lifetime JP5357857B2 (ja) 1998-07-23 2010-10-29 抗ガン剤及びｄｎａ複製阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010102499A Pending JP2010202655A (ja) 1998-07-23 2010-04-27 チオアラビノフラノシル化合物の製造方法
JP2010243705A Expired - Lifetime JP5357857B2 (ja) 1998-07-23 2010-10-29 抗ガン剤及びｄｎａ複製阻害剤

Country Status (9)

Country Link
US (5) US6576621B1 (OSRAM)
EP (3) EP2332551B1 (OSRAM)
JP (3) JP4719356B2 (OSRAM)
AT (1) ATE531376T1 (OSRAM)
AU (1) AU747012B2 (OSRAM)
CA (1) CA2338415C (OSRAM)
ES (3) ES2402799T3 (OSRAM)
NZ (1) NZ509405A (OSRAM)
WO (1) WO2000004866A2 (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884882B2 (en) 2014-02-18 2018-02-06 Fujifilm Corporation Method for producing thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate
US9896471B2 (en) 2012-03-28 2018-02-20 Fujifilm Corporation Salt of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine
US10059734B2 (en) 2014-10-31 2018-08-28 Fujifilm Corporation Thionucleoside derivative or salt thereof, and pharmaceutical composition
US11141421B2 (en) 2018-01-29 2021-10-12 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
US11369625B2 (en) 2016-08-31 2022-06-28 Fujifilm Corporation Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402799T3 (es) * 1998-07-23 2013-05-09 Southern Research Institute Prepreparación de compuestos de tioarabinofuranosilo y utilización de los mismos
WO2004018494A1 (ja) * 2002-08-22 2004-03-04 Geneticlab Co., Ltd. ４’−チオヌクレオチド
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
WO2008118852A1 (en) * 2007-03-23 2008-10-02 Southern Research Institute Method for treating and preventing arthritis
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
JP5622725B2 (ja) * 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
JP6351107B2 (ja) * 2014-02-18 2018-07-04 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6245527B2 (ja) * 2014-03-24 2017-12-13 富士フイルム株式会社 チオラン環もしくはチアン環骨格を有する化合物の製造方法
EP3303361A1 (en) * 2015-05-27 2018-04-11 Idenix Pharmaceuticals LLC Nucleotides for the treatment of cancer
WO2017091836A1 (en) * 2015-11-25 2017-06-01 University Of South Carolina Enhancement of cytarabine activity by inhibiting cdk8/19
AU2019256465B2 (en) * 2018-04-19 2024-10-03 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
EP3993806A4 (en) * 2019-06-05 2023-09-13 Southern Research Institute THIARABINE AND THIARABINE PRODRUG BASED TREATMENTS
CA3176543A1 (en) 2020-04-23 2021-10-28 Mark J. Suto Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004033A1 (en) * 1989-09-15 1991-04-04 Southern Research Institute 2'-deoxy-4'-thioribonucleosides as antiviral and anticancer agents
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
JPH04505929A (ja) * 1989-12-08 1992-10-15 シティ・オブ・ホープ ヒトの抗癌剤の耐性の回避
JPH09249690A (ja) 1995-07-14 1997-09-22 Yamasa Shoyu Co Ltd ４’−チオアラビノプリンヌクレオシド
JPH0925289A (ja) 1995-07-14 1997-01-28 Yamasa Shoyu Co Ltd ４’−チオアラビノピリミジンヌクレオシドの製造方法
JP2943690B2 (ja) 1996-04-17 1999-08-30 日本電気株式会社 セル衝突検出装置
AU749561B2 (en) 1997-05-09 2002-06-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules having endonuclease and/or catalytic activity
US6548657B1 (en) * 1997-06-09 2003-04-15 Ribozyme Pharmaceuticals, Inc. Method for screening nucleic acid catalysts
WO1999043690A1 (en) 1998-02-25 1999-09-02 Rational Drug Design Laboratories L-4'-arabinofuranonucleoside compound and medicine composition comprising the same
ES2402799T3 (es) * 1998-07-23 2013-05-09 Southern Research Institute Prepreparación de compuestos de tioarabinofuranosilo y utilización de los mismos

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9896471B2 (en) 2012-03-28 2018-02-20 Fujifilm Corporation Salt of 1-(2-deoxy-2-fluoro-4-thio-β-D-arabinofuranosyl)cytosine
US9884882B2 (en) 2014-02-18 2018-02-06 Fujifilm Corporation Method for producing thiolane skeleton-type glycoconjugate, and thiolane skeleton-type glycoconjugate
US10059734B2 (en) 2014-10-31 2018-08-28 Fujifilm Corporation Thionucleoside derivative or salt thereof, and pharmaceutical composition
US10385089B2 (en) 2014-10-31 2019-08-20 Fujifilm Corporation Thionucleoside derivative or salt thereof, and pharmaceutical composition
US11369625B2 (en) 2016-08-31 2022-06-28 Fujifilm Corporation Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
US11141421B2 (en) 2018-01-29 2021-10-12 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer

Also Published As

Publication number Publication date
EP1100512A2 (en) 2001-05-23
EP1100512A4 (en) 2001-10-10
NZ509405A (en) 2004-10-29
US20100216797A1 (en) 2010-08-26
US20060287320A1 (en) 2006-12-21
US7138385B2 (en) 2006-11-21
JP2011032281A (ja) 2011-02-17
CA2338415C (en) 2006-10-10
CA2338415A1 (en) 2000-02-03
US6576621B1 (en) 2003-06-10
EP2332551B1 (en) 2013-01-09
EP2335706A1 (en) 2011-06-22
US20050038025A1 (en) 2005-02-17
US6870052B2 (en) 2005-03-22
ES2376862T3 (es) 2012-03-20
ES2438144T3 (es) 2014-01-16
ES2402799T3 (es) 2013-05-09
AU5123999A (en) 2000-02-14
JP2010202655A (ja) 2010-09-16
EP1100512B1 (en) 2011-11-02
ATE531376T1 (de) 2011-11-15
WO2000004866A2 (en) 2000-02-03
WO2000004866A3 (en) 2000-04-20
EP2335706B1 (en) 2013-10-23
EP2332551A1 (en) 2011-06-15
AU747012B2 (en) 2002-05-09
US7691820B2 (en) 2010-04-06
WO2000004866A9 (en) 2000-08-10
US20030203872A1 (en) 2003-10-30
JP2002521318A (ja) 2002-07-16
US8178510B2 (en) 2012-05-15
JP5357857B2 (ja) 2013-12-04

Similar Documents

Publication Publication Date Title
JP5357857B2 (ja) 抗ガン剤及びｄｎａ複製阻害剤
MC1742A1 (fr) Procede pour preparer un derive de 3'-azido-3'desoxythymigline et procede pour preparer une formulation pharmaceutique le contenant
JP2022508786A (ja) 環状ジヌクレオチド化合物及びその使用
JPH09504541A (ja) ５‐フルオロウラシル誘導体
RU2194511C2 (ru) Применение 5-этинилурацила в качестве инактиватора урацилредуктазы, фармацевтическая композиция, способ ее получения, фармацевтическая композиция для усиления действия или снижения токсичности 5-фторурацила
JP3094036B2 (ja) 酵素不活性化剤
CN105263501A (zh) 具有抗转移活性的糖-类似物含磷杂环
JPWO1992004028A1 (ja) 抗腫瘍効果増強剤及び抗腫瘍剤
GB1570555A (en) Anti-cancer composition
EP1673353A1 (en) Transition state structure and inhibitors of thymidine phosphorylases
EP0788507A1 (en) L-pyranosyl nucleosides
AU2002300586B2 (en) A method for treating solid tumors
JPS6223723B2 (OSRAM)
JPH0413328B2 (OSRAM)
WO2002098397A2 (en) Therapeutic compositions for modulating the immune response in a mammal and use thereof
JPS61254526A (ja) 経口投与用抗腫瘍剤
JPH0717869A (ja) ５−フェネチル−２′−デオキシウリジンを含有する抗腫瘍効果増強剤及び抗腫瘍剤
CA2203675A1 (en) L-erythrosyl nucleosides
JPS6223724B2 (OSRAM)

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060130

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20080707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100125

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100125

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100326

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101029

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20101029

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110404

R150 Certificate of patent or registration of utility model

Ref document number: 4719356

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140408

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees